期刊文献+

紫杉醇联合抗HER2单抗对人卵巢癌细胞株A2780的作用 被引量:1

United Effects of Paclitaxel and Anti-HER2 Mono-Antibody (mAb) on Human Ovarian Cancer Cell Strain A2780
下载PDF
导出
摘要 目的:体外观察紫杉醇及抗HER2单抗对人卵巢癌细胞株A2780增殖的抑制作用及两者联合应用时的抑制率及相互作用。方法:采用MTT法测定两者单用或合用对A2780的增殖抑制率,利用中效原理判定两药合用的效果,用流式细胞仪观察细胞凋亡及细胞周期的变化。结果:两种药单独应用时随药物剂量增加,其效应也增加,紫杉醇的中效浓度为6.98 nmol· L-1,抗HER2单抗的中效浓度为8.69μg·ml-1;两药合用时它们的中效浓度为2.92 nmol·L-1+0.49μg·ml-1。大剂量(紫杉醇>13.02 nmol·L-1,抗HER2单抗>2.17 μg·ml-1)合用时是拮抗作用(CI>1),小剂量(紫杉醇<13.02 nmol·L-1,抗HER2 单抗<2.17 μg·ml-1)合用时是协同作用(CI<1)。结论:紫杉醇联合抗HER2单抗对人卵巢癌细胞株A2780的生长有抑制作用,它们合用时大剂量是拮抗,而小剂量则为协同作用。 Objective: To observe the inhibiting effects of paclitaxel (TAX) and anti HER2 mAb on human ovarian cancer cell strain A2780 and the inhibiting rate and interaction when the two drugs were used together. Method: The inhibition of TAX and anti HER2 mAb on A2780 cells used together or separately was measured by MTT assay. The interaction effect of two drugs was analyzed with median-effect principle. The changes of cell period and the apoptosis were observed by using flow cytometer (FCM). Result: The effects of the individual drugs were enhanced as drug dosage increased. The median concentration of Tax was 6.98 nmol·L^-1 and that of anti-HER2 mAb was 8.69 μg·ml^-1, The median concentration of combination of two drugs was 2.92 nmol·L^-1 + 0.49 μg·ml^-1.The interaction of two drugs was antagonistic at higher concentration (Concentration of Tax 〉 13.02 nnmol·L^-1, Concentration of antiHER2 mAb 〉 2.17μg·ml^-1 ) ( CI 〉 1 ) and synergistic at lower concentration ( Concentration of Tax 〈 13.02 nnmol·L^-1, Concentration of anti-HER2 mAb 〈 2. 177μg·ml^-1) ( CI 〈 1 ). Conclusion : The united effect of the Tax and anti - HER2 mAb on A2780 cells is antagonistic at higher concentration and synergistic at lower concentration.
出处 《中国药师》 CAS 2005年第8期623-625,共3页 China Pharmacist
基金 国家自然科学基金资助项目(No.30300429)
关键词 药物联合应用 中效原理 卵巢癌 紫杉醇 抗HER2单抗 Drug combination Median-effect principle Ovarian cancer Paclitaxel nti HER2 mAb
  • 相关文献

参考文献8

二级参考文献23

  • 1Carraway KL, Perez A, Idris N, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epitheha: to protect and to survive[J]. Prog Nucleic Acid Res Mol Biol, 2002, 71:149- 185.
  • 2Wang S, Saboorian MH, Frenkel E, et al. laboratory assessment of the slams of HER-2/neu protein and oncogene in breast cancer specimens:comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays[J]. J Clin Pathol, 2000, 53(5) :374- 381.
  • 3Scheurle D, Jahanzeb M, Aronsohn RS, et al. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Herceptin test[J]. Anticancer Res, 2000, 20(3B) :2091 -2096.
  • 4Seliger B, Rongcun Y, Atkins D, et al. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA_-A2. 1-restricted cytotoxic T lymphocytes[J]. Int J Cancer, 2000, 87(3) :349- 359,.
  • 5Ross JS, Gray K, Gray GS, et al. Anticancer antibodies[J], Am J Clin Pathol, 2003, 119(4) :472 - 485.
  • 6Schneider JW, Chang AY, Garratt A, et al. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study[J]. Semin Oncol, 2002, 29(3 Suppl 11 ) :22 - 28.
  • 7Jahanzeb M. Trastuzumab-based combinations in metastatic breast cancer: bow to make a choice[J]. Clin Breast Cancer, 2003, 4(1):28-38.
  • 8Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer[J]. Semin Oncol, 2002,29(3 Suppl 11 ) :38 - 43.
  • 9Klapper LN, Waterman H, Sela M, et al. Tumor-inhibitory antibodies to HFB2/ErbB2 may act by recruiting, c-Cbl and enhancing ubiquitination of HFM-2[J]. Cancer Res, 2000,60(13) :3384 - 3388.
  • 10Nagy P, Jenei A, Damjanovich S, et al. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy [ J ]. Pathol Oncol Res,1999, 5(4) :255 - 271.

共引文献117

同被引文献10

  • 1于佩瑶,方凤奇,刘基巍.多西紫杉醇联合顺铂治疗晚期胃癌临床观察[J].药物流行病学杂志,2006,15(2):69-71. 被引量:3
  • 2Mu L,Feng SS.Vitamin E TPGS used as emulsifier in the solvent e-vapomtion/extraction technique for fabrication of polymeric nanosph-eres for favrication of polymeric nanospheres for controlled release ofpaditaxel(Taxol)[J].J Control Rel,2002,80:129-144
  • 3Mu L,Feng SS.A novel controlled release formulation for the anti-cancer drug paclitaxel(Taxol):PICA nanoparticles containing vita-min E TPGS[J].J Control Rel,2003,86:33-48
  • 4Langer R.Biomaterials in Drug Delivery and Tissue Engineering:OreLaboratory's Experience[J].Chem Res,2000,33(2):94-101
  • 5Leong KW,Brott BC,Langer R.Bioerodable polyanhydride as drugcarrier matrices,I:Characterization,degradation,and release char-acteristics[J].J Biomed Mater Res,1985,19:941-955
  • 6Leong KW,Amore PD,Marietta M,et al.Bioeredable polyanhydrideas drug carrier matrices II:Biocompatibility and chemical reactivity[J].J Biomed Mater Res,1986,20:51-64
  • 7Sampath P,Brem H.Implantable slow-release chemotherapeutic pol-ymers for the treatment of malignant brain tumors[J].Cancer Con-trd,1998,5(2):130-137
  • 8Walter KA,Tmasrgo RJ,Olivi A,et al.Intratumoral chemotherapy[J].Neurosurgery,1995,37(6):1128-1145
  • 9Domb AJ,Israel ZH,Elmalak O,et al.Preparation and character-ization of camustine loaded polyanhydride wafers for treating braintumors[J].Pharm Res,1999,16(5):762-765
  • 10张景勍,张志荣,秦少容,谭群友,钟国跃,陈开杰.紫杉醇磁性长循环脂质体的研究[J].中国药学杂志,2003,38(7):520-522. 被引量:11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部